Gastroenterology
Volume 138, Issue 3 , Pages 896-904, March 2010

Proton-Pump Inhibitor Use Is Not Associated With Osteoporosis or Accelerated Bone Mineral Density Loss

  • Laura E. Targownik

      Affiliations

    • Section of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • Corresponding Author InformationReprint requests Address requests for reprints to: Laura Targownik, MD, MSHS, 805G-715 McDermot Avenue, Winnipeg, Manitoba, Canada R3N 0V6
    • ,
  • Lisa M. Lix

      Affiliations

    • School of Public Health, University of Saskatchewan, Saskatoon, Saskatchewan, Canada
    • ,
  • Stella Leung

      Affiliations

    • Section of Gastroenterology, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • ,
  • William D. Leslie

      Affiliations

    • Manitoba Centre for Health Policy, Department of Community Health Sciences, Faculty of Medicine, Winnipeg, Manitoba, Canada
    • Section of Nuclear Medicine, Department of Radiology, University of Manitoba, Winnipeg, Manitoba, Canada
    • Section of Endocrinology & Metabolism, Division of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

Received 17 March 2009; accepted 12 November 2009. published online 19 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 30.00 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 Conflicts of interest The authors disclose the following: Dr Laura Targownik has served on advisory boards for Janssen-Ortho Canada and Astra-Zeneca Canada and on the speaker's bureau for Astra-Zeneca Canada. Both companies either currently or at one time marketed particular proton pump inhibitors in Canada. The remaining authors disclose no conflicts.

 Funding Dr Targownik is supported by a Canadian Institutes of Health Research New Investigator Grant in Osteoporosis, and by Osteoporosis Canada. Dr Leslie is supported by the Canadian Institutes of Health Research. Dr Lix is supported by a CIHR New Investigator Award. This project was funded by a grant from the Canadian Institutes of Health Research Regional Partnership Program and the Manitoba Health Research Council.

PII: S0016-5085(09)02030-7

doi:10.1053/j.gastro.2009.11.014

Gastroenterology
Volume 138, Issue 3 , Pages 896-904, March 2010

Article Tools